Prem N Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8651900/publications.pdf Version: 2024-02-01



DDEM N CLIDTA

#	Article	IF	CITATIONS
1	Recent Advances in the Surfactant and Controlled Release Polymer-based Solid Dispersion. Current Pharmaceutical Design, 2022, 28, 1643-1659.	1.9	2
2	Tumor micro-environment targeted collagenase-modified albumin nanoparticles for improved drug delivery. Journal of Drug Delivery Science and Technology, 2022, 71, 103366.	3.0	6
3	Implication of methylselenocysteine in combination chemotherapy with gemcitabine for improved anticancer efficacy. European Journal of Pharmaceutical Sciences, 2022, 176, 106238.	4.0	6
4	Benzimidazole-Based Organic–Inorganic Gold Nanohybrids Suppress Invasiveness of Cancer Cells by Modulating EMT Signaling Cascade. ACS Applied Bio Materials, 2021, 4, 470-482.	4.6	1
5	Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends. Pharmacological Research, 2021, 169, 105618.	7.1	23
6	Mechanistic investigation of synergistic interaction of tocopherol succinate with a quinoline-based inhibitor of mammalian target of rapamycin. Journal of Pharmacy and Pharmacology, 2021, , .	2.4	3
7	Design, synthesis and comparative analysis of triphenyl-1,2,3-triazoles as anti-proliferative agents. European Journal of Medicinal Chemistry, 2020, 207, 112813.	5.5	21
8	Drug resistance in cancer: mechanisms and tackling strategies. Pharmacological Reports, 2020, 72, 1125-1151.	3.3	118
9	Recent advances in tumor microenvironment associated therapeutic strategies and evaluation models. Materials Science and Engineering C, 2020, 116, 111229.	7.3	30
10	Recent Advances in Strategies for Extracellular Matrix Degradation and Synthesis Inhibition for Improved Therapy of Solid Tumors. Current Pharmaceutical Design, 2020, 26, 5456-5467.	1.9	11
11	Hyaluronic Acid-Tacrolimus Bioconjugate: Synthesis, Characterization, and Pharmacokinetic Investigation of an Acid-Responsive Macromolecular Prodrug. ACS Applied Bio Materials, 2019, 2, 4728-4736.	4.6	16
12	Recent Advances in Formulation Strategies for Efficient Delivery of Vitamin D. AAPS PharmSciTech, 2019, 20, 11.	3.3	27
13	Gemcitabine and betulinic acid co-encapsulated PLGAâ^'PEG polymer nanoparticles for improved efficacy of cancer chemotherapy. Materials Science and Engineering C, 2019, 98, 764-771.	7.3	66
14	Therapeutic applications of betulinic acid nanoformulations. Annals of the New York Academy of Sciences, 2018, 1421, 5-18.	3.8	48
15	Tacrolimus: An updated review on delivering strategies for multifarious diseases. European Journal of Pharmaceutical Sciences, 2018, 114, 217-227.	4.0	48
16	CD44 targeted PLGA nanomedicines for cancer chemotherapy. European Journal of Pharmaceutical Sciences, 2018, 121, 47-58.	4.0	36
17	Synthesis, characterization and augmented anticancer potential of PEC-betulinic acid conjugate. Materials Science and Engineering C, 2017, 73, 616-626.	7.3	39
18	Development and evaluation of long-circulating nanoparticles loaded with betulinic acid for improved anti-tumor efficacy. International Journal of Pharmaceutics, 2017, 531, 153-166.	5.2	55

Prem N Gupta

#	Article	IF	CITATIONS
19	Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor. Biomedicine and Pharmacotherapy, 2017, 95, 856-864.	5.6	38
20	Development and mechanistic insight into enhanced cytotoxic potential of hyaluronic acid conjugated nanoparticles in CD44 overexpressing cancer cells. European Journal of Pharmaceutical Sciences, 2017, 97, 79-91.	4.0	33
21	Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy. European Journal of Pharmaceutical Sciences, 2016, 92, 183-193.	4.0	26
22	Improved efficacy of cisplatin in combination with a nano-formulation of pentacyclic triterpenediol. Materials Science and Engineering C, 2016, 68, 109-116.	7.3	19
23	PLGA nanoparticles augmented the anticancer potential of pentacyclic triterpenediol in vivo in mice. RSC Advances, 2016, 6, 74586-74597.	3.6	23
24	Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine. European Journal of Pharmaceutical Sciences, 2016, 93, 147-162.	4.0	50
25	Synthesis and characterization of TPCS–gemcitabine prodrug micelles for pancreatic cancer therapy. RSC Advances, 2016, 6, 60126-60137.	3.6	53
26	Recent Advances in Chitosan-Based Nanomedicines for Cancer Chemotherapy. Springer Series on Polymer and Composite Materials, 2016, , 229-259.	0.7	11
27	Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine. International Journal of Pharmaceutics, 2015, 492, 80-91.	5.2	81
28	Reduced toxicological manifestations of cisplatin following encapsulation in folate grafted albumin nanoparticles. Life Sciences, 2015, 142, 76-85.	4.3	19
29	Targeted Drug Delivery Systems for Pancreatic Cancer. Journal of Biomedical Nanotechnology, 2014, 10, 3462-3482.	1.1	38
30	Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opinion on Drug Delivery, 2014, 11, 121-138.	5.0	62
31	Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. International Journal of Pharmaceutics, 2014, 470, 51-62.	5.2	43
32	Biodegradable polymeric system for cisplatin delivery: Development, in vitro characterization and investigation of toxicity profile. Materials Science and Engineering C, 2014, 38, 85-93.	7.3	38
33	Development and evaluation of paclitaxel loaded PLGA:poloxamer blend nanoparticles for cancer chemotherapy. International Journal of Biological Macromolecules, 2014, 69, 393-399.	7.5	26
34	Paclitaxel Formulations: Challenges and Novel Delivery Options. Current Drug Delivery, 2014, 11, 666-686.	1.6	117
35	Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy. Current Cancer Drug Targets, 2014, 14, 419-433.	1.6	44